Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy

• Asıl Yazarlar: Laura Keller (Yazar), Nicolas Guibert (Yazar), Anne Casanova (Yazar), Stephanie Brayer (Yazar), Magali Farella (Yazar), Myriam Delaunay (Yazar), Julia Gilhodes (Yazar), Elodie Martin (Yazar), Gisèle Balagué (Yazar), Gilles Favre (Yazar), Anne Pradines (Yazar), Nicolas Meyer (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Medical Journals Sweden, 2018-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Antibodies targeting immune checkpoints were recently approved for metastatic melanoma. However, not all patients will respond to the treatment and some will experience grade III-IV immune-related adverse events. Therefore, early identification of non-responder patients would greatly aid clinical pr...